Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

医学 肝细胞癌 核医学 新辅助治疗 肝切除术 实体瘤疗效评价标准 放射科 进行性疾病 内科学 化疗 癌症 外科 切除术 乳腺癌
作者
Qiang Li,Xiaolan Wang,Deju Li,Yulong Liu,Kangshou Liu,Junjie Liang,Jianfang Sun,Quan Jiang,Jiexing Li,Zhilong Liu,Jian Gong,Leyang Xiang,Zhidong Jia,Zhiwei Chen,Mingrong Cao,Yuchuan Jiang
出处
期刊:Journal of Visualized Experiments [MyJOVE]
卷期号: (207)
标识
DOI:10.3791/66407
摘要

This study showcases a comprehensive treatment protocol for high-risk hepatocellular carcinoma (HCC) patients, focusing on the combined use of Y-90 transarterial radioembolization (TARE) and Programmed Cell Death-1 (PD-1) inhibitors as neoadjuvant therapy. Highlighted through a case report, it offers a step-by-step reference for similar therapeutic interventions. A retrospective analysis was conducted on a patient who underwent hepatectomy following Y-90 TARE and PD-1 inhibitor treatment. Key demographic and clinical details were recorded at admission to guide therapy selection. Y-90 TARE suitability and dosage calculation were based on Technetium-99m (Tc-99m) macroaggregated albumin (MAA) perfusion mapping tests. Lesion coverage by Y-90 microspheres was confirmed through single photon emission computed tomography/computed tomography (SPECT/CT) fusion imaging, and adverse reactions and follow-up outcomes were meticulously documented. The patient, with a 7.2 cm HCC in the right hepatic lobe (T1bN0M0, BCLC A, CNLC Ib) and an initial alpha-fetoprotein (AFP) level of 66,840 ng/mL, opted for Y-90 TARE due to high recurrence risk and initial surgery refusal. The therapy's parameters, including the lung shunting fraction (LSF) and non-tumor ratio (TNR), were within therapeutic limits. A total of 1.36 GBq Y-90 was administered. At 1 month post-therapy, the tumor shrank to 6 cm with partial necrosis, and AFP levels dropped to 21,155 ng/mL, remaining stable for 3 months. After 3 months, PD-1 inhibitor treatment led to further tumor reduction to 4 cm and AFP decrease to 1.84 ng/mL. The patient then underwent hepatectomy; histopathology confirmed complete tumor necrosis. At 12 months post-surgery, no tumor recurrence or metastasis was observed in follow-up sessions. This protocol demonstrates the effective combination of Y-90 TARE and PD-1 inhibitor as a bridging strategy to surgery for HCC patients at high recurrence risk, providing a practical guide for implementing this approach.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
欢呼青易发布了新的文献求助10
1秒前
ZN发布了新的文献求助10
2秒前
2秒前
Hhd完成签到,获得积分10
3秒前
包子完成签到,获得积分20
3秒前
4秒前
4秒前
刘二豆应助小宇采纳,获得10
5秒前
海的精神完成签到,获得积分10
6秒前
KING完成签到,获得积分10
6秒前
胖虎发布了新的文献求助10
7秒前
7秒前
Wayne发布了新的文献求助10
7秒前
顺顺尼完成签到 ,获得积分10
8秒前
美满冷安发布了新的文献求助10
8秒前
精明的甜瓜应助Noah采纳,获得10
9秒前
精明的甜瓜应助Noah采纳,获得10
9秒前
精明的甜瓜应助Noah采纳,获得10
9秒前
科目三应助春风知我意采纳,获得10
9秒前
精明的甜瓜应助Noah采纳,获得10
9秒前
精明的甜瓜应助Noah采纳,获得10
9秒前
能干的邹完成签到 ,获得积分10
10秒前
PhysicsXX完成签到,获得积分10
10秒前
海的精神发布了新的文献求助10
10秒前
六斤发布了新的文献求助10
11秒前
14秒前
完美世界应助ZN采纳,获得10
16秒前
Wayne完成签到,获得积分10
17秒前
Colin发布了新的文献求助10
19秒前
19秒前
小学生发布了新的文献求助10
20秒前
lingkai发布了新的文献求助10
20秒前
23秒前
23秒前
yang完成签到,获得积分10
26秒前
26秒前
完美世界应助linmo采纳,获得10
27秒前
27秒前
YY发布了新的文献求助10
27秒前
结实的以莲完成签到,获得积分10
28秒前
高分求助中
【请各位用户详细阅读此贴后再求助】科研通的精品贴汇总(请勿应助) 10000
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 1000
Global Eyelash Assessment scale (GEA) 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4046092
求助须知:如何正确求助?哪些是违规求助? 3583836
关于积分的说明 11390716
捐赠科研通 3311111
什么是DOI,文献DOI怎么找? 1822153
邀请新用户注册赠送积分活动 894354
科研通“疑难数据库(出版商)”最低求助积分说明 816171